BOLD News and Press, Audentes Therapeutics Inc. From 08/06/19

SAN FRANCISCO , Aug. 6, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today reported its financial results for ...

SAN FRANCISCO , July 30, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, will host a conference call and webcast to report ...

For life sciences investors, the gene therapy market is one of the most interesting plays in the industry today. In simple terms, the US National Library of Medicine defines gene therapy as ways to prevent or treat diseases by using genes. It has the potential to treat patients by inse...

Biotech Pulse Biotech shares are up this year, as represented by the Nasdaq Biotechnology Index ( IBB ), which is the industry benchmark, and the S&P Select Biotechnology Index ( XBI ), after a sharp decline in 2018. This is a welcome respite for biotech investors. However, it has not ...

Market Pulse The month of May thus far has been mostly a downward ride with an occasional rise, proving to be a mere bunny bump, as indexes have eroded persistently on the lack of a trade resolution with China, an outcome that at one point was considered to be almost in the bag. This is rais...

SAN FRANCISCO , May 29, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced that it has appoi...

Shares of Audentes Therapeutics ( BOLD ) have risen by over 130% since my initial recommendation a couple years back. However, peformance is slightly negative since my January 2018 update piece . At ASGCT (American Society of Gene & Cell Therapy) meeting this year, the company unveile...

Biotech Pulse The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have struggled since March as the broader healthcare sector ( XLV ) declined following growing momentum amongst the presidential candidates for a universal healthcare plan. This was at a time when the broader ma...

SAN FRANCISCO , May 8, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced that it will particip...

Audentes Therapeutics , Inc. (BOLD) Q12 2019 Results Earnings Conference Call May 7, 2019 4:30 PM ET Company Participants Andrew Chang – Head-Investor Relations Matt Patterson – Chairman and Chief Executive Officer Conference Call Participants Anupam Rama ȁ...